Table 3.
FDA approved RTK inhibitors and antibodies currently in use.
| Name | Target | Company | Class |
|---|---|---|---|
| Bevacizumab (Avastin) | VEGF | Genentech Imclone/Bristol-Meyers |
Monoclonal antibody |
| Cetuximab (Erbitux) | EGFR | Squib | Monoclonal antibody |
| Panitumumab (Vectibix) | EGFR | Amgen | Monoclonal antibody |
| Ranibizumab (Lucentis) | VEGF | Genentech | Monoclonal antibody |
| Trastuzumab (Herceptin) | Erb2 | Genentech | Monoclonal antibody |
| Pegaptanib (Macugen) | VEGF | OSI/Pfizer | RNA Aptamer |
| Dasatinib (Sprycel) | Src/Bcr-Abl | Bristol-Meyers Squib | Small molecule |
| Erlotinib (Tarceva) | EGFR | Genentech/OSI | Small molecule |
| Gefitinib (Iressa) | EGFR | AstraZeneca | Small molecule |
| Imatinib (Gleevec) | Bcr-Abl | Novartis | Small molecule |
| Lapatinib (Tykerb) | EGFR/Erb2 | GSK | Small molecule |
| Nilotinib (Tasigna) | Bcr-Abl VEGFR1/2/3 |
Novartis | Small molecule |
| Pazopanib (Votrient) | PDGFR/c-kit | GlaxoSmithKline | Small molecule |
| Sorafenib (Nexavar) | RAF/VEGFR2/PDGFRB VEGFR2/PDGFRB |
Onyx/Bayer | Small molecule |
| Sunitinib (Sutent) | c-kit/FLT3 | Pfizer | Small molecule |